Back to search
FDAFDA · Food and drugs·Recall number D-0992-2022

Anagrelide Capsules USP, 0.5 mg, 100-count bottles, Rx Only, Manufactured in India For: TEVA PHARMACEUTICALS USA, Inc., North Wales, PA 19454. NDC 0172-5241-60.

Published June 8, 2022 · Recall initiated: May 11, 2022

Summary

FDA records drug Class I recall D-0992-2022, published June 8, 2022 and initiated May 11, 2022. Recalling firm: Teva Pharmaceuticals USA Inc; Status: Terminated; Reported quantity: 4224 cartons; Lot: Lot # GD01090, Exp 05/2022. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications- Low Out-Of-Specification results obtained during stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA Inc
Distributor
Distributed Nationwide in the USA
Lot
Lot # GD01090, Exp 05/2022
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Anagrelide Capsules USP, 0.5 mg, 100-count bottles, Rx Only, Manufactured in India For: TEVA PHARMACEUTICALS USA, Inc., North Wales, PA 19454. NDC 0172-5241-60. recalled?

Yes. FDA published recall D-0992-2022 on June 8, 2022. Reported hazard: Failed Dissolution Specifications- Low Out-Of-Specification results obtained during stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter